CD3-Reactive Multispecific Polypeptides for Manufacturable T Cell Recruitment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bispecific formats for recruiting cytotoxic T cells to target cancer cells face challenges such as manufacturing issues, stability problems, low expression titers, poor solubility, and adverse side effects, limiting their clinical efficacy and patient compliance.
Innovation Solution
Development of multispecific polypeptides with high affinity for CD3 on T cells and a target antigen, allowing T cell activation independent of MHC recognition, comprising immunoglobulin single variable domains (ISVs) that direct T cells to target cells and induce cytotoxic activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional bispecific antibody formats are used to recruit T cells to cancer cells, then T cell activation can be achieved, but manufacturing issues, stability problems, low expression titers, and poor solubility occur
Solution Approach 1:
The patent divides the antibody structure into separate functional components: a first immunoglobulin molecule binding CD3 on T cells and a second immunoglobulin molecule binding the target antigen on cancer cells. This segmentation allows independent optimization of each component's manufacturing and functional properties, resolving the contradiction between achieving reliable T cell activation and maintaining ease of manufacture.
Solution Approach 2:
The patent introduces a linker molecule as an intermediary that connects the first and second immunoglobulin molecules. This intermediary component enables the formation of the bispecific structure while allowing independent production and purification of each immunoglobulin, thereby maintaining manufacturing feasibility while achieving reliable T cell recruitment and activation.
2Reliability
If conventional bisspecific antibody formats are used, then T cell recruitment can be achieved, but stability problems and poor solubility occur
Solution Approach 1:
The patent optimizes the linker molecule's physical and chemical parameters (such as length, flexibility, and chemical composition) to ensure the bispecific structure maintains stability and solubility. By carefully selecting and adjusting these parameters, the patent achieves reliable T cell recruitment while preventing molecular aggregation and degradation.
3Reliability
If conventional bispecific antibody formats are used, then T cell activation can be achieved, but low expression titers and adverse side effects occur
Solution Approach 1:
The patent segments the bispecific antibody into separately expressible immunoglobulin components, allowing each to be produced and purified independently. This segmentation enables optimization of expression systems for each component, thereby increasing overall expression titers while reducing adverse side effects through improved purity and reduced immunogenicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The multispecific polypeptides effectively activate T cells to kill target cells with high specificity and efficacy, reducing immune escape mechanisms and improving clinical outcomes.
Implementation Method 1
said first ISV has high affinity for/binds to CD3
Implementation Method 2
said at least one further ISV has high affinity for/binds to an antigen present on a target cell
Data Source
AI summary
T cell recruiting polypeptides are provided that bind CD3 on a T cell. The polypeptides can be used in methods for treatment of cancers.